Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects

Clinical Pharmacokinetics

Volumn 47, Issue 6, 2008, Pages 399-415

  Pérez Ruixo, Juan José ^a,b   Krzyzanski, Wojciech ^c   Hing, Jeremy ^d  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c UNIVERSITY AT BUFFALO   (United States)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Pharmacodynamic modelling; Recombinant erythropoietin, pharmacodynamics; Recombinant erythropoietin, pharmacokinetics; Reticulocytes

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; CELL AGING; CELL DIFFERENTIATION; CELL MATURATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; ERYTHROPOIESIS; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MEAN RESIDENCE TIME; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CLINICAL TRIALS AS TOPIC; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETICULOCYTE COUNT; RETICULOCYTES;

EID: 43649083687     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847060-00004     Document Type: Article

References (32)

1. Koury MJ, Sawyer ST, Brandt S. New insights into erythropoiesis. Opin Hematol 2002; 9: 93-100
2. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003; 228: 1-14
3. Krantz SB. Erythropoietin. Blood 1991; 77: 419-34
4. Chang CC, Kass L. Clinical significance of immature reticulocyte fraction determined by automated reticulocyte counting. Am J Clin Pathol 1997; 108: 69-73
5. Tatsumi N, Izumi T. Reticulocyte maturation index as a useful diagnostic parameter. Sysmes Int 1991; 1: 23-8
6. Sowade O, Sowade B, Brilla K. Kinetics of reticulocyte maturity fractions and indices and iron status during therapy with epoetin beta (recombinant human erythropoietin) in cardiac surgery patients. Am J Hematol 1997; 55: 89-96
7. Brugnara C. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci 2000; 37: 93-130
8. Major A, Bauer C, Breymann C, et al. rh-Erythropoietin stimulates immature reticulocyte release in man. Br J Haematol 1994; 87: 605-8
9. Al-Huniti NH, Widness JA, Schmidt RL, et al. Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis. J Pharmacokinet Pharmacodyn 2005; 32: 359-76
10. Krzyzanski W, Pérez-Ruixo JJ. An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects. Pharm Res 2007; 24: 758-71
11. Harker LA, Roskos LK, Marzec UM, et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 2000; 95: 2514-22
12. Roskos LK, Lum P, Lockbaum P, et al. Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 2006; 46: 747-57
13. Simeoni M, Magni P, Cammia C, et al. Predictive pharmacokinetic- pharmacodynamic modeling of tumor growth kinetics in xenograft models after administrations of anticancer agents. Cancer Res 2004; 64: 1094-101
14. Cheung WK, Goon BL, Guilfoyle MC, et al. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 1998; 64: 412-23
15. Ratnasingam L. An open-label, randomized, parallel design study to investigate the pharmacokinetic and pharmacodynamic profiles of single subcutaneously administered doses of epoetin alfa in healthy male volunteers. Protocol EPOPHI-380. Raritan (NJ): Johnson & Johnson Pharmaceutical Research and Development, 2001. (Data on file)
16. Grune W. New developments in flow cytochemistry technology. Atlas Automated Cytochem Hematol 1996; 94: 1-6
17. Holford N. Wings for NONMEM [online]. Available from URL: http://wfn.sourceforge.net [Accessed 2008 Mar 4]
18. Olsson-Gisleskog P, Jacqmin P, Pérez-Ruixo JJ. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects. Clin Pharmacokinet 2007; 46: 159-73
19. Zhang L, Beal SL, Sheiner LB. Simultaneous vs sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 2003; 30: 387-404
20. Sun Y-N, Jusko WJ. Transit compartments versus gamma distribution function to model signal transduction process in pharmacodynamics. J Pharm Sci 1998; 87: 732-7
21. Mager DE, Jusko WJ. Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther 2001; 70: 210-6
22. Efron B, Tibshirani R. An introduction to the bootstrap. London: Chapman and Hall, 1993
23. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001; 28: 171-92
24. Ramakrishnan R, Cheung WK, Wacholtz MC, et al. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 2004; 44: 991-1002
25. Krzyzanski W, Jusko WM, Wacholtz MC, et al. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci 2005; 26: 295-306
26. Pérez-Ruixo JJ, Kimko HC, Chow AT, et al. Population cell life span models for effects of drugs following indirect mechanisms of action. J Pharmacokinet Pharmacodyn 2005; 32: 767-93
27. Spivak JL. The mechanism of action of erythropoietin. Int J Cell Cloning 1986; 4: 139-66
28. Bugelski PJ, Nesspor T, Volk A, et al. Pharmacodynamics of recombinant human erythropoietin in murine bone marrow. Pharm Res 2008; 25: 369-78
29. Trial J, Rice L, Alfrey CP. Erythropoietin withdrawal alters interactions between young red blood cells, splenic endothelial cells, and macrophages: an in vitro model of neocytolysis. J Invest Med 2001; 49: 335-45
30. Agoram B, Heatherington AC, Gastonguay MR. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS J 2006 Sep 1; 8 (3): E552-63
31. Wiczling P, Krzyzanski W. Flow cytometric assessment of homeostatic aging of reticulocytes in rats. Exp Hematol 2008; 36: 119-27
32. Woo S, Krzyzanski W, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. J Pharmacol Exp Ther 2006; 319: 1297-306